Lung cancer remains the leading cause of cancer death in the United States, with the majority of lung cancer cases associated with smoking.27,28 Despite successful efforts to decrease tobacco use, 37% of American adults are former or current smokers and are therefore at higher risk for developing malignancy.28 Approximately 6% of adults in the US will be diagnosed with lung and bronchus cancer in their lifetime and an estimated 131,880 people will die of this disease in 2021.27 The 5-year survival rate is 21.7%.27
While lung cancer generally has a poor prognosis, evidence supports that annual screening for high-risk individuals can decrease lung cancer death by 20%.28-30 The USPSTF, ACS, and American Thoracic Society recommend screening with annual low-dose CT as a proven test with high sensitivity and acceptable specificity for the detection of lung cancer in high-risk persons (Table 7).28,30,31 The USPSTF recommends lung cancer screening for people aged 50 to 80 years who have smoked at least 20 pack-years over their lifetime and still smoke or have quit smoking within the last 15 years.28 Clinicians should exclude from screening patients with significant or life-limiting comorbidities and those with metal implants or devices in the chest or back.30
Low-dose CT has significant limitations and potential harms, including a significant risk of obtaining false-positive results and overdiagnosis resulting in the need for invasive procedures and more frequent testing.29 Patients should be counseled that screening does not detect all lung cancers, of the risk associated with radiation exposure, and that positive screening does not necessarily prevent lung cancer death.29 Despite these screening guidelines, providers must not overlook smoking cessation counseling for lung cancer prevention. 28-30
Table 7. Lung Cancer Screening Guidelines28-30
|USPSTF28 (2021)||ACS30 (2018)||ACCP29 (2018)|
|Annual LDCT for adults aged 50-80 y with a 20-pack year smoking history and currently smoke or have quit within the past 15 years||Annual LDCT for adults aged 55-74 y with a 30-pack year smoking history who currently smoke or have quit within the past 15 years||Annual LDCT for adults aged 55-77 y with a 30-pack year smoking history and currently smoke or have quit within the past 15 years|
Implications for Clinical Practice
Providers play a significant role in recommending cancer screening and preventing cancer deaths with early dedication by incorporating cancer screening guidelines into routine care. Taking a holistic approach to cancer screening that uses evidence-based screening guidelines and a discussion of patient’s health goals, available resources, and values is central to cancer prevention. For every discussion around cancer screening, providers should engage in shared decision-making with patients regarding harms and benefits of screening. Some high-risk groups, such as those with hereditary cancer syndromes and history of exposure to known carcinogens, may require a more intensive cancer screening strategy. Lastly, clinicians can engage in various health promotion strategies such as immunization, weight loss, and smoking cessation to reduce overall cancer risk.
Michalle Ramirez-McLaughlin, MS, FNP-C, is an assistant clinical professor with the Department of Family Health Care Nursing at the University of California, San Francisco. She maintains a primary care practice at the Marin Community Clinics, a federally qualified health care center in Novato, CA. She is passionate about providing equitable, high-quality care across the lifespan with an emphasis on wellness and prevention.
Michelle Buchholz, MSN, BSN, FNP-BC, is an assistant clinical professor with the Department of Family Healthcare Nursing at University of California, San Francisco. She maintains a clinical practice with Ravenswood Family Health Center, a federally qualified health center in East Palo Alto, CA.
Gabriel Schwartz, MSN, BSN, FNP-BC, is a nurse practitioner with the Department of Gastrointestinal Medical Oncology at University of California, San Francisco. He specializes in the care of patients with liver cancer, bile duct cancer, colon cancer, and other gastrointestinal malignancies.
Gabriel Schwartz, MSN, BSN, FNP-BC, has served as a consultant and speaker for Eisai, Inc, and consultancy fees from Exelixis, Inc. Michalle Ramirez-McLaughlin, FNP-C, and Michelle Buchholz, MSN, BSN, FNP-BC, have no relevant disclosures
1. Ahmad FB, Cisewski JA, Miniño A, Anderson RN. Provisional mortality data – United States, 2020. MMWR Morb Mortal Wkly Rep. 2021;70(14):519-522. doi:10.15585/mmwr.mm7014e1
2. Cancer stat facts: common cancer sites. National Cancer Institute, Surveillance, Epidemiology, and End Results Program. Accessed July 21, 2021. https://seer.cancer.gov/statfacts/html/all.html
3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7-30. doi:10.3322/caac.21442
4. Smith RA, Andrews KS, Brooks D, et al. Cancer screening in the United States, 2017: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2017;67(2):100-121. doi:10.3322/caac.21392
5. Eeles RA, Tobias JS, Berg CD, eds. Cancer Prevention and Screening: Concepts, Principles and Controversies. Hoboken, NJ: Wiley; 2018.
6. Myers ER, Moorman P, Gierisch JM, et al. Benefits and harms of breast cancer screening: a systematic review. JAMA. 2015;314(15):1615-1634. doi:10.1001/jama.2015.13183
7. Fontham ETH, Wolf AMD, Church TR, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA Cancer J Clin. 2020;70(5):321-346. doi:10.3322/caac.21628
8. The American College of Obstetricians and Gynecologists. Updated cervical cancer screening guidelines. April 2021. Accessed July 21, 2021.
9. Melnikow J, Henderson JT, Burda BU, Senger CA, Durbin S, Soulsby MA. Screening for cervical cancer with high-risk human papillomavirus testing: a systematic evidence review for the U.S. Preventive Services Task Force. Agency for Healthcare Research and Quality (US); 2018. Report No.: 17-05231-EF-1.
10. Perkins RB, Guido RS, Castle PE, et al. 2019 ASCCP Risk-Based Management Consensus Guidelines Committee. 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2020;24(2):102-131. doi:10.1097/LGT.0000000000000525
11. American Cancer Society. Breast cancer facts & figures 2019-2020. American Cancer Society, Inc. 2019. Accessed July 27, 2019. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/breast-cancer-facts-and-figures-2019-2020.pdf
12. American Cancer Society. Cancer Facts & Figures. American Cancer Society; 2021. Accessed July 27, 2021. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2021/cancer-facts-and-figures-2021.pdf
13. Mandelblatt JS, Stout NK, Schechter CB, et al. Collaborative modeling of the benefits and harms associated with different U.S. breast cancer screening strategies. Ann Intern Med. 2016;164(4):215. doi:10.7326/M15-1536
14. Practice Bulletin Number 179: Breast cancer risk assessment and screening in average-risk women. Obstet Gynecol. 2017;130(1):e1-e16. doi:10.1097/AOG.0000000000002158
15. Oeffinger KC, Fontham ETH, Etzioni R, et al. Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society. JAMA. 2015;314(15):1599. doi:10.1001/jama.2015.12783
16. Siu AL, Bibbins-Domingo K, Grossman DC, LeFevre ML; US Preventive Services Task Force. Convergence and divergence around breast cancer screening. Ann Intern Med. 2016;164(4):301-302. doi:10.7326/M15-3065
17. Nelson HD, Cantor A, Humphrey L, et al. Screening for Breast Cancer: A Systematic Review to Update the 2009 U.S. Preventive Services Task Force Recommendation. Agency for Healthcare Research and Quality (US); 2016. Report No.: 14-05201-EF-1. Accessed July 27, 2021. https://www.ncbi.nlm.nih.gov/books/NBK343819/
18. Schrager SB, Phillips G, Burnside E. A simple approach to shared decision making in cancer screening. Fam Pract Manag. 2017;24(3):5-10.
19. Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Prostate Cancer. Accessed July 28, 2021. https://seer.cancer.gov/statfacts/html/prost.html
20. US Preventive Services Task Force, Grossman DC, Curry SJ, et al. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018;319(18):1901-1913. doi:10.1001/jama.2018.3710
21. Wolf AMD, Wender RC, Etzioni RB, et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010;60(2):70-98. doi:10.3322/caac.20066
22. Carter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate cancer: AUA Guideline. J Urol. 2013;190(2):419-426. doi:10.1016/j.juro.2013.04.119.
23. Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Colorectal Cancer. Accessed July 29, 2021. https://seer.cancer.gov/statfacts/html/colorect.html
24. US Preventive Services Task Force. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325(19):1965–1977. doi:10.1001/jama.2021.6238
25. Wolf AMD, Fontham ETH, Church TR, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J Clin. 2018;68(4):250-281. doi:10.3322/caac.21457
26. Gates TJ. Screening for cancer: concepts and controversies. Am Fam Physician. 2014;90(9):625-631.
27. Surveillance, Epidemiology, and End Results. Cancer stat facts: lung and bronchus cancer. Accessed July 29, 2021. https://seer.cancer.gov/statfacts/html/lungb.html
28. US Preventive Services Task Force, Krist AH, Davidson KW, et al. Screening for lung cancer: US Preventive Services Task Force recommendation statement. JAMA. 2021;325(10):962-970. doi:10.1001/jama.2021.1117
29. Mazzone PJ, Silvestri GA, Patel S, et al. Screening for lung cancer: CHEST Guideline and expert panel report. Chest. 2018;153(4):954-985. doi:10.1016/j.chest.2018.01.016
30. Wender R, Fontham ETH, Barrera E, et al. American Cancer Society lung cancer screening guidelines. CA Cancer J Clin. 2013;63(2):106-117. doi:10.3322/caac.21172